2-{3-[3-(4-fluorophenoxy)-5-{[(4-hydroxy-4-isobutyl-1-piperidinyl)carbonyl]amino}phenoxy]phenoxy}-2-methylpropanoic acid | 1428900-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{3-[3-(4-fluorophenoxy)-5-{[(4-hydroxy-4-isobutyl-1-piperidinyl)carbonyl]amino}phenoxy]phenoxy}-2-methylpropanoic acid
• 英文别名: 2-[3-[3-(4-Fluorophenoxy)-5-[[4-hydroxy-4-(2-methylpropyl)piperidine-1-carbonyl]amino]phenoxy]phenoxy]-2-methylpropanoic acid；2-[3-[3-(4-fluorophenoxy)-5-[[4-hydroxy-4-(2-methylpropyl)piperidine-1-carbonyl]amino]phenoxy]phenoxy]-2-methylpropanoic acid
• CAS: 1428900-29-1
• 化学式: C₃₂H₃₇FN₂O₇
• 分子量: 580.653
• InChiKey: IOUWBVYLTBTBHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• PHENYL DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150126486A1

  公开（公告）日：2015-05-07

  The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

  化合物的化学式为（I-1）：其中所有符号的含义与说明书中描述的相同，具有两个环状基团，特别是在特定的取代位置上有苯氧基团，因此具有较高的人类S1P2拮抗活性。 因此，该化合物可用作S1P2介导的疾病的治疗剂，例如由血管收缩，纤维化和呼吸系统疾病引起的疾病。
• 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2762476A1

  公开（公告）日：2014-08-06

  The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally Ra-substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally Ra-substituted C1-C8 alkyl group, an optionally Ra-substituted C2-C6 alkenyl group, an optionally Ra-substituted C2-C6 alkynyl group, an optionally Rb-substituted C3-C10 cycloalkyl group, an optionally Rb-substituted C6-C14 aromatic hydrocarbon group, an optionally Rb-substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally Rb-substituted 4-to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally Ra-substituted C1-C6 alkyl group; and B represents an optionally Rc-substituted unsaturated heterocyclic group).

  本发明提供了由下通式（I）代表的化合物或其盐，该化合物具有抑制 Syk 的作用（式中 R1 代表氢原子或任选 Ra 取代的 C1-C6 烷基；A代表氢原子、任选Ra取代的C1-C8烷基、任选Ra取代的C2-C6烯基、任选Ra取代的C2-C6炔基、任选Rb取代的C3-C10环烷基、任选Rb取代的C6-C14芳烃基、任选 Rb 取代的 4 至 10 元不饱和杂环基团，或任选 Rb 取代的 4 至 10 元饱和杂环基团，或任选与 R1 及其键合的氮原子一起形成 4 至 10 元不饱和杂环或 4 至 10 元饱和杂环；R2 代表氢原子或任选 Ra 取代的 C1-C6 烷基；以及 B 代表任选 Rc 取代的不饱和杂环基团）。
• Phenyl derivative
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10117861B2

  公开（公告）日：2018-11-06

  The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

  式 (I-1) 的化合物： 其中所有符号的含义与说明书中所述的相同，具有两个环状基团，特别是特定取代位置上的苯氧基，因此具有较高的人体 S1P2 拮抗活性。因此，该化合物可用作 S1P2 介导的疾病（如血管收缩、纤维化和呼吸系统疾病引起的疾病）的治疗剂。
• US20140343038A1
  申请人：——

  公开号：US20140343038A1

  公开（公告）日：2014-11-20
• US8975409B2
  申请人：——

  公开号：US8975409B2

  公开（公告）日：2015-03-10